A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06788639
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lisocabtagene maraleucel — BIOLOGICAL
    According to the United States Prescribing Information

Study Details

The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Key Dates

Start date
Feb 4, 2025
Status verified
Feb 2025
Primary completion
Jun 30, 2044
Completion
Jun 30, 2044

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Participants treated with lisocabtagene maraleucel

Primary Outcome Measure

Adverse events (AEs) [ Time Frame: Up to 15 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Center for International Blood and Marrow Transplant Research (CIBMTR)MilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By research site
Center for International Blood and Marrow Transplant Research (CIBMTR)· Milwaukee, WI

Related Studies